CorVel Co. (NASDAQ:CRVL – Get Free Report) Director Jeffrey J. Michael sold 10,477 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $116.45, for a total transaction of $1,220,046.65. Following the completion of the transaction, the director now owns 568,310 shares in the company, valued at approximately $66,179,699.50. This trade represents a 1.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
CorVel Trading Up 1.2 %
Shares of CRVL stock opened at $106.17 on Wednesday. CorVel Co. has a 1 year low of $76.20 and a 1 year high of $128.61. The firm’s 50 day moving average is $112.55 and its 200-day moving average is $114.20. The firm has a market capitalization of $5.45 billion, a price-to-earnings ratio of 62.45 and a beta of 1.06.
CorVel (NASDAQ:CRVL – Get Free Report) last announced its earnings results on Tuesday, February 4th. The business services provider reported $0.46 earnings per share (EPS) for the quarter. CorVel had a net margin of 10.12% and a return on equity of 32.22%.
Hedge Funds Weigh In On CorVel
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded shares of CorVel from a “hold” rating to a “buy” rating in a research report on Wednesday, February 26th.
Check Out Our Latest Analysis on CRVL
CorVel Company Profile
CorVel Corporation provides workers’ compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.
Featured Articles
- Five stocks we like better than CorVel
- Learn Technical Analysis Skills to Master the Stock Market
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.